Neophrogenic Fibrosing Dermopathy: Are ACE Inhitors the Missing Link? [L1]

Archives of Dermatology

Volumn 140, Issue 11, 2004, Pages 1401-

  Fazeli, Amin ^b   Lio, Peter A ^a   Liu, Vincent ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 4; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1;

CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; HEMODIALYSIS; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; KIDNEY FAILURE; LETTER; NEPHROGENIC FIBROSING DERMOPATHY; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUVA; SKIN FIBROSIS; FIBROSIS; KIDNEY DISEASE; PATHOLOGY; SKIN DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FIBROSIS; HUMANS; KIDNEY DISEASES; SKIN DISEASES;

EID: 8144229864     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Streams BN, Liu V, Liegeois N, Moschella SM. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol. 2003;48:42-47.
2. Molteni A, Ward WF, Tsao CH, et al. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des. 2003;9:751-761.
3. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003;25:204-209.